WORLD'S LARGEST MARKET RESEARCH RESOURCE — 1,519,265 REPORTS

 
 
• SEARCH FOR A REPORT

Viewing report

Search
Enter keywords, a title or a report id number below.
Advanced

• ORDER BY FAX

Order By Fax

• SELECT SITE CURRENCY

Select a currency for use throughout the site



  • Electronic (PDF) Information Icon
  • Site License Information Icon
  • Enterprisewide Information Icon
Live Chat Live Help Software for Website

BIOCON - Rising Expense - Just The Start

MP Advisors, October 2011

BIOS 2QFY11 result largely in line with our estimates with higher than expected increase in staff and other expenses that was compensated by a lower than expected increase in the R&D expenses. On the business front, there was nothing significant with continued growth in biopharma owing to statins, immunosuppresants and insulin. While costs are all set to increase with higher R&D costs on the horizon as they pursue many projects, visibility on those projects still remain uncertain. Syngene & Clinigene are also turning around as expected. We continue to remain cautious about the biosimilars opportunity (Pfizer and Mylan deals) and about BIOS basic research program with Oral Insulin’s less encouraging PhIII data.We thus reiterate our market Perform on Biocon with target price of Rs. 324

- Biocon
- Fidaxomicin
- Insulin Pens
- Oral Insulin
- Generic
- BIIB

Customers who bought this item also bought